ANDA 78383, held by Chartwell RX. Pioglitazone Hydrochloride.
As of Nov 21, 2026, ANDA 78383 (Pioglitazone Hydrochloride), held by Chartwell RX, was first approved by FDA on Mar 12, 2013, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 12, 2013 | Original application | Approved | None posted |
| Pioglitazone HydrochlorideEQ 15MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Pioglitazone HydrochlorideEQ 30MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Pioglitazone HydrochlorideEQ 45MG BASE · tablet;oral | Pioglitazone Hydrochloride | Discontinued |
| Mar 12, 2023 | Supplement 3 | Approved | None posted |
| Mar 12, 2013 | Original application | Approved | None posted |
| Mar 12, 2013 | Supplement 1 | Approved | None posted |
| Mar 12, 2013 | Supplement 2 | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters